Market research
HIK.LSE Hikma Pharmaceuticals PLC
LSE GBP Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 3B
- P/E ratio
- 11.51
- Analyst target
- 2002.2455
- Dividend yield
- 5.7%
- Beta
- 0.66
Profile
Company facts
- Exchange
- LSE
- Currency
- GBP
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- GB00B0LCW083
- Market cap
- 3B
- P/E ratio
- 11.51
- Analyst target
- 2002.2455
- Dividend yield
- 5.7%
- Beta
- 0.66
About
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the HIK.LSE discussion.
5 years, 5 months ago
Hikma Pharmaceuticals PLC is currently in a long term uptrend where the price is trading 4.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.3.
Hikma Pharmaceuticals PLC's total revenue sank by 0.0% to $580M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $150M since the same quarter in the previous year.
Finally, its free cash flow fell by 69.2% to $33M since the same quarter in the previous year.
Based on the above factors, Hikma Pharmaceuticals PLC gets an overall score of 2/5.